STX expects ACCRUFER full U.S. control to lift EBIT and margins
Shield Therapeutics (STX) says full U.S. commercial control of ACCRUFER is expected to nearly double EBIT and expand gross margins to 75%-80% with no upfront payment and immediate accretion.
Full U.S. commercial control of ACCRUFER is expected to nearly double EBIT and expand gross margins to 75%-80%, with no upfront payment and immediate accretion.
The integrated sales force and platform support future product additions and continued growth.Based on Shield Therapeutics Plc [STX] Statu…